ArticleTransboundary and emerging diseases2026
An Exploratory One Health Investigation of Mycobacterium tuberculosis Complex at the Camel-Human Interface in Abu Dhabi Emirate, United Arab Emirates.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Exploratory One Health Investigation of Mycobacterium tuberculosis Complex at the Camel-Human Interface in Abu Dhabi Emirate, United Arab Emirates.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This exploratory cross-sectional One Health study characterized LIODetect TB-ST antibody reactivity in dromedary camels and abattoir workers in Abu Dhabi Emirate and investigated tuberculosis-compatible lesions in slaughtered camels. Sera from 356 camels sampled from farms and livestock holdings (izbas), 393 camels presented for slaughter at Al Bawadi Abattoir, and 86 abattoir workers were screened with LIODetect TB-ST. All 25 LIODetect-reactive slaughtered camels underwent detailed postmortem examination; nonreactive slaughtered camels were not examined postmortem. Lesions identified in two reactive camels were evaluated by histopathology, Ziehl-Neelsen staining, and IS6110 polymerase chain reaction (PCR). LIODetect reactivity was detected in 33/356 field camels (9.3%, 95% CI: 6.5%-12.8%), 25/393 slaughtered camels (6.4%, 95% CI: 4.2%-9.2%), and 3/86 workers (3.5%, 95% CI: 0.7%-9.9%). No recorded characteristic was associated with reactivity among field camels. Among slaughtered camels, age group and body condition showed exploratory statistical associations with reactivity, but category-specific estimates were imprecise. Two of the 25 reactive slaughtered camels (8.0%) had granulomatous lymphadenitis with acid-fast bacilli, and lesion tissue from both animals contained IS6110-detectable Mycobacterium tuberculosis complex (MTBC) DNA. LIODetect TB-ST has not been validated for prevalence estimation in dromedaries; therefore, these proportions describe assay reactivity rather than true infection prevalence. Because postmortem examination was restricted to reactive animals, the 2/25 finding cannot estimate lesion prevalence, false-negative frequency, or positive predictive value. The three reactive workers represent an occupational-health surveillance signal, not evidence of active tuberculosis or camel-to-human transmission. Systematic meat inspection, validated camel diagnostics, culture and species-level molecular characterization, traceable animal movements, and linked veterinary and occupational-health surveillance are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.